- Previous Close
1.2450 - Open
1.2950 - Bid 1.0050 x --
- Ask 1.2950 x --
- Day's Range
1.2600 - 1.2950 - 52 Week Range
0.9680 - 2.8900 - Volume
5,077 - Avg. Volume
18,373 - Market Cap (intraday)
46.002M - Beta (5Y Monthly) 0.37
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.20
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide to treat patients with sepsis, septic shock, and severe malaria conditions, which is under Phase Ib clinical study. The company was founded in 2011 and is headquartered in Stockholm, Sweden.
www.modustx.comRecent News: MODTX.ST
View MorePerformance Overview: MODTX.ST
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MODTX.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MODTX.ST
View MoreValuation Measures
Market Cap
46.00M
Enterprise Value
38.00M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
6.71
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-79.43%
Return on Equity (ttm)
-156.87%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-15.54M
Diluted EPS (ttm)
-0.4500
Balance Sheet and Cash Flow
Total Cash (mrq)
4.38M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-9.03M